Hill Ward Henderson represented QOL Medical, LLC (QOL Medical) in its acquisition of Evoke Pharma, Inc. (NASDAQ: EVOK) (Evoke). The transaction was structured as a tender offer for shares of Evoke at a price of $11 per share, followed by a second-step merger. The transaction closed on December 17, 2025.
Evoke is a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray.
QOL Medical is a privately held biopharmaceutical company specializing in treatments for GI and rare diseases.
The Hill Ward Henderson corporate and M&A team representing QOL Medical was led by corporate shareholder John Connery, with assistance from associates Ryan Divers, Amanda Anderson and Hailey Schlotthauer.
The securities team was led by corporate shareholder Roland Chase, with assistance from associates Quinn Cockrell and Gabby Strasser.
The deal team also included executive compensation & employee benefits shareholder Kirsten Vignec, tax shareholder Prestin Weidner and associates Alexandra Prati and Aaron Ostler, employment shareholder Jeff Wilcox, and intellectual property associate Patrick Reid.